Tumor cells deficient in HMGB1 exhibit compromised capacity to induce ICD and anti-tumor immune responses, however, TLR4 agonists rescued the chemotherapy-induced anti-tumor immune responses [27]. This evidence concerns the gene TLR4 and neoplasm.